Bedside to bench: interfering with leukemic stem cells.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 18463658.
- Also identified by DOI 10.1038/nm0508-494 and PMC identifier 3490184.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Kinase inhibitors such as imatinib (Gleevec) have improved the outlook for many patients with chronic myeloid leukemia and related blood disorders. But such drugs fail to target the leukemia stem cell population and may not be curative. Krause and Van Etten discuss several clinical studies that suggest that interferon-α may provide a solution by selectively eliminating leukemic stem cells–although only more basic research will tell us whether this is true and how it may happen.
Medical subject headings
- Antineoplastic Agents
- Interferon Type I
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Myeloid Progenitor Cells
- Piperazines
- Pyrimidines